TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03795948

Intervention type: OTHER
Group type: OTHER
Intervention: PROMs
Description: Introduction and assessment of the ICHOM standard set consisting of demographic and medical data as well as questionnaires filled in by patients, shortly after admission to the stroke unit, at discharge, and at 90 and 360 days after stroke.~Specifically the intervention includes an assembly of clinical records, in particular records of complications, recurrence of disease and mortality. Further patients will be required to complete a questionnaire assessing their situation in terms of housing and symptom burden as well as their self-perceived autonomy and quality of life.~Telephone assessments will be administered to support patients if necessary and validate their responses.
Study: NCT00990886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride
Description: 15 mg once daily for 12 weeks
Study: NCT04560842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A high flow oxygen device.
Description: The HFNC group use high flow oxygen device for 48 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional oxygen therapy
Description: Conventional oxygen device
Study: NCT03702699

Intervention type: DEVICE
Intervention: Auricular point detector
Description: This device is only for auricular detection. No additional intervention will be delivered.

Intervention type: DEVICE
Intervention: Auricular point detector
Description: This device is only for auricular detection. No additional intervention will be delivered.
Study: NCT02835066

Intervention type: OTHER
Intervention: Integrated Fitness Assessment
Description: Undergo function/fitness assessment

Intervention type: PROCEDURE
Intervention: Psychosocial Assessment and Care
Description: Undergo psychosocial health assessments

Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
Study: NCT02638532

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Foot Fat Pad Grafting
Description: Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
Study: NCT02062697

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lavage of the Cavum uteri and proximal fallopian tubes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liquid-PAP smear
Study: NCT04017962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir Pill
Description: Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks. Patients receiving oral medication will be administered a pill diary for drug compliance purposes. This will be administered and reconciled in clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: Collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180.
Study: NCT01207960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
Study: NCT02094040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receive municipality-based follow-up visit
Description: Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
Study: NCT00229801

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: MRI
Study: NCT04254757

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two different treatment
Description: One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two different treatment
Description: One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
Study: NCT00632294

Intervention type: PROCEDURE
Intervention: Tissue Sample
Description: A leftover sample of the removed allograft bone will be collected.
Study: NCT01163617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in current syringe
Description: Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in current syringe
Description: Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in Physiolis syringe
Description: Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in Physiolis syringe
Description: Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in current autoinjector
Description: Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in current autoinjector
Description: Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in current autoinjector
Description: Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in current autoinjector
Description: Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in Physiolis autoinjector
Description: Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in Physiolis autoinjector
Description: Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in Physiolis autoinjector
Description: Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in Physiolis autoinjector
Description: Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
Study: NCT01250938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESI - Community Outreach
Description: This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
Study: NCT03739892

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard stroke rehabilitation
Description: standard rehabilitation according to the french standard care and to the severity of the patient
Study: NCT03965364

Intervention type: DEVICE
Intervention: INCRAFT
Description: Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
Study: NCT03972540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful eating intervention
Description: A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
Study: NCT02066116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinect-based rehabilitation plus occupational therapy
Description: The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham virtual rehabilitation education plus occupational therapy
Description: For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
Study: NCT02349880

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: shared decision making training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: shared decision making training
Study: NCT01267032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care
Description: A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Integrated Care
Description: A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment for Insomnia
Description: A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Desensitization Treatment for Insomnia
Description: A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
Study: NCT00437762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A Injection
Description: Botulinum Toxin A Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo Injection
Study: NCT02873663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma and head hair collection
Description: Plasma and head hair collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma and head hair collection
Description: Plasma and head hair collection
Study: NCT02428400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG1050
Description: TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: adenovirus reference material (ARM) buffer
Study: NCT01769586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT00583544

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TC-2216
Description: Multiple ascending dose groups will be explored.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-2216
Description: Multiple ascending dose groups will be explored.
Study: NCT05604950

Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions

Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions
Study: NCT00658619

Intervention type: DRUG
Group type: OTHER
Intervention: 400 µg Brimonidine Tartrate Implant
Description: 400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.

Intervention type: DRUG
Group type: OTHER
Intervention: 400 µg Brimonidine Tartrate Implant
Description: 400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.

Intervention type: DRUG
Group type: OTHER
Intervention: 200 µg Brimonidine Tartrate Implant
Description: 200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.

Intervention type: DRUG
Group type: OTHER
Intervention: 200 µg Brimonidine Tartrate Implant
Description: 200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham (no implant)
Description: Sham in one or both eyes on Day 1 and Month 6.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham (no implant)
Description: Sham in one or both eyes on Day 1 and Month 6.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham (no implant)
Description: Sham in one or both eyes on Day 1 and Month 6.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham (no implant)
Description: Sham in one or both eyes on Day 1 and Month 6.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (no implant)
Description: Sham in one or both eyes on Day 1 and Month 6.
Study: NCT03752892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention -1-leg cycle training
Description: partitioned aerobic exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care - 2-leg cycle training
Description: conventional aerobic exercise training
Study: NCT00677222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMI MultiStem®
Description: AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
Study: NCT04877600

Intervention type: OTHER
Intervention: dual task performance
Description: dual task performance measurement
Study: NCT02164617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair-bound Senior Elastic Band exercise program (WSEB)
Description: Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
Study: NCT02387112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early VAD implantation
Description: Implantation of a left ventricular assist device
Study: NCT01603160

Intervention type: BEHAVIORAL
Intervention: Quality Improvement
Description: There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized.
Study: NCT04015063

Intervention type: OTHER
Group type: OTHER
Intervention: Anti-Aging Skin Care product
Description: Primary Subjects will use P29429-01 as an anti-aging skin care product on full face twice a day for 12-week.
Study: NCT02936999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
Study: NCT00776256

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beta-glucan and fructooligosaccharide
Description: 1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beta-glucan and fructooligosaccharide
Description: 1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beta-glucan and fructooligosaccharide
Description: 1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beta-glucan and fructooligosaccharide
Description: 1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
Study: NCT04398472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KIND Challenge
Description: The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
Study: NCT02898467

Intervention type: OTHER
Intervention: diabetics
Description: additional blood and urine collection during usual medical care endarterectomy samples during usual medical care

Intervention type: OTHER
Intervention: non-diabetics
Description: additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
Study: NCT01626170

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00747877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous hematopoietic stem cell transplantation on day 0.
Study: NCT00916578

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
Study: NCT03104023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staple line inversion
Description: A staple line inversion will be performed with a running suture of Polypropylene 2/0

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Staple line buttressing
Description: The gastric section will be performed with a stapler with preloaded buttress material
Study: NCT02886351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
Study: NCT00849056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo weekly subcutaneous injection
Study: NCT03808766

Intervention type: OTHER
Group type: OTHER
Intervention: embolization
Description: Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: embolization
Description: Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: embolization
Description: Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
Study: NCT02807922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02242617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure (PAP)
Description: Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure (PAP)
Description: Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement Splints (MAS)
Description: Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement Splints (MAS)
Description: Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep